Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025Alvelestat granted ...

The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatmen ...

Aromatase inhibitors (AIs) such as anastrozole ... Oatp1b2 as transporters that regulate the initial step in the elimination of AIs. Genetic deficiency of this transport mechanism in mice was ...

Zinc deficiency, in contrast, is associated with decreased testosterone ... Another compound in honey called chrysin is thought to be a potent aromatase inhibitor. These natural compounds block ...

Progression-free survival at 24 months was 61.4% for patients with MMR deficiency who received dostarlimab and ... multiple targets have been established (table 2). Progestins and aromatase inhibitors ...